The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 695-704

  Barchfeld, G L ^a   Hessler, A L ^a   Chen, M ^a   Pizza, M ^b   Rappuoli, R ^b   Van Nest, G A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHIRON VACCINES   (Italy)

Author keywords

Adjuvant; Influenza; Intranasak

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; IMMUNOGENICITY; INFLUENZA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI PROTEINS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NASAL MUCOSA; POLYSORBATES; SQUALENE;

EID: 0033605094     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00252-7     Document Type: Article

References (42)

1. Renegar K.B. Influenza virus infections and immunity: a review of human and animal models. Laboratory Animal Science. 42:1992;222-232.
2. Guink N.E., Kris R.M., Goodman-Snitkoff G., Small P.A. Jr., Mannino R.J. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 7:1989;147-151.
3. Clements M.L. Influenza vaccines. In: Ellis R.W., editor. Vaccines: new approaches to immunological problems. Stoneham, Butterworth-Heinemann, 1992, p. 129-150.
4. Shaw M.W., Arden N.H., Maassab H.F. New aspects of influenza viruses. Cinical Microbiology Reviews. 5:1992;74-92.
5. Ada G.L., Jones P.D. The immune response to influenza infection. Current Topics in Microbiology and Immunology. 128:1986;3-54.
6. Potter C.W., Path M.R.C., Oxford J.S. Determinants of immunity to influenza in man. British Medical Bulletin. 35:1979;69-75.
7. Murphy B.R., Webster R.G. Orthomyxoviruses. In: Fields B.N., Knipe P.M., Howley, P.M., editors. Fields virology, chap. 46. Philadelphia: Lippincott-Raven, 1996, p. 1397-1445.
8. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D. Jr., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases. 169:1994;68-76.
9. Wu H.-Y., Russell M.W. Nasal lymphoid tissue, intranasal immunization and compartmentalization of the common mucosal immune system. Immunologic Research. 16:1997;187-201.
10. Tamura S.-i., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. The Journal of Immunology. 149:1992;981-988.
11. Tamura S.-i., Funato H., Hirabayashi Y., Kikuta K., Suzuki Y., Nagamine T., Aizawa C., Nakagawa M., Kurata T. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine. 8:1990;479-485.
12. Taylor P.M., Askonas B.A. Influenza nucleoprotein-specific cytotoxic T cell clones are protective in vivo. Immunology. 58:1986;417-420.
13. Yewdell J.W., Bennick J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proceedings of the National Academy of Science USA. 82:1985;1785-1789.
14. Palache A.M., Beyer W.E.P., Sprenger M.J.W., Masurel N., de Jonge S., Vardy A., Charpentier B., Noury J., van Beek W.C.A., Borst R.J.A., Ligthart G.J., Keren G., Rubinstein E. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine. 11:1993;3-9.
15. Kuno-Sakai H., Kimura M., Ohta K., Shimojima R., Oh Y., Fukumi H. Developments in mucosal influenza virus vaccines. Vaccine. 12:1994;1303-1308.
16. Kaji M., Kaji Y., Kaji M., Ohkuma K., Honda T., Oka T., Sakoh M., Nakamura S., Kurachi K., Sentoku M. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine. 10:1992;663-667.
17. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals. 25:1997;209-213.
18. Oh Y., Ohta K., Kuno-Sakai H., Kim R., Kimura M. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine. 10:1992;506-511.
19. Waldman R.H., Wood S.H., Torres E.J., Small P.A. Jr. Influenza antibody response following aerosal administration of inactivated virus. American Journal of Epidemiology. 91:1970;575-584.
20. Gruber W.C., Hinson H.P., Holland K.L., Thompson J.M., Reed G.W., Wright P.F. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. Journal of Infectious Diseases. 168:1993;1282-1285.
21. Tomoda T., Morita H., Kurashige T., Maassab H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-δ production and local IgA response. Vaccine. 13:1995;185-190.
22. Treanor J.J., Mattison H.R., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R.F. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Annals of Internal Medicine. 117:1992;625-633.
23. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell M.F., Newman M.J., editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995, p. 277-296.
24. Pizza M., Domenighini M., Hol W., Giannelli V., Fontana M.R., Giullani M.M., Magagnoli C., Peppoloni S., Manetti R., Rappuoli R. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Molecular Microbiology. 14:1994;51-60.
25. Higgins D.A., Carlson J.R., Van Nest G.A. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine. 14:1996;478-484.
26. Jackson R.J., Fujihashi K., Kiyono H., McGhee J.R. Luminometry: a novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses. Journal of Immunological Methods. 190:1996;189-197.
27. Ugozzoli M., O'Hagan D.T., Ott G.S. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology. 93:1998;563-571.
28. Heirholzer J.C., Suggs M.T. Standardized viral hemagglutination and hemagglutination-inhibition tests. Applied Microbiology. 18:1969;816.
29. Valensi J.-P., Carlson J.R., Van Nest G.A. Systemic cytokine profiles in balb/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. Journal of Immunology. 153:1994;4029-4039.
30. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiological Reviews. 56:1992;622-647.
31. Giannelli V., Fontana M.R., Giuliani M.M., Guangcai D., Rappuoli R., Pizza M. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site of in the protease-sensitive loop. Infection and Immunity. 65:1997;331-334.
32. Delmas A., Partidos C.D. The binding of chimeric peptides to GM1 gangliosides enables induction of antibody responses after intranasal immunization. Vaccine. 14:1996;1077-1082.
33. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infection and Immunity. 65:1997;2821-2828.
34. Tamura S.-i., Samegai Y., Kurata H., Kikuta K., Nagamine T., Chikara A., Kurata T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 7:1989;257-262.
35. Oka T., Honda T., Morokuma K., Ginnaga A., Ohkuma K., Sakoh M. Enhancing effects of pertussis toxin B oligoomer on the immunogenicity of influenza vaccine administered intranasally. Vaccine. 12:1994;1255-1258.
36. Hashigucci K., Ogawa O., Ishidate T., Yamashita R., Kamiya H., Watanabe K., Hattori N., Sato T., Suzuki Y., Nagamine T., Aizawa C., Tamura S., Kurata T., Oya A. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherchia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 14:1996;113-119.
37. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., Douce G., De Magistris M.T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat labile enterotoxin as a mucosal adjuvant. Infection and Immunity. 64:1996;974-979.
38. Barchfeld G.L., Chen M., Pizza M., Rappuoli R. A nontoxic mutant of E. coli enterotoxin, LTK63, enhances HIV p24 gag CTL induction in mice by intranasal immunization. 1998, in preparation.
39. Lukacher A.E., Braciale V.L., Braciale T.J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. Journal of Experimental Medicine. 160:1984;814-826.
40. Gupta R.K., Griffin P. Jr., Chang A.-C., Rivera R. Anderson R., Rost B., Cecchini D., Nicholson M., Siber G. The role of adjuvants and delivery systems in modulation of immune response to vaccines. In: Cohen S., Shafferman A., editors. Novel strategies in design and production of vaccines, New York: Plenum Press, 1996, p. 105-113.
41. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. The Journal of Infectious Diseases. 173:1996;285-290.
42. Powers D.C., Belshe R.B. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and 'original antigenic sin'. Journal of Infectious Diseases. 169:1994;1125-1129.